While PIK3CA mutant prostate cancers have been shown to respond to p110α isoform-specific inhibition, previous work by us and others has shown that targeting p110α alone in prostate cancers with PTEN loss is not efficacious, owing to p110β dependency [21,144,168,169]. This evidence concerns the gene PIK3CA and prostate carcinoma.